Under this award, the Hawaii Biotech team will continue screening potent anti-toxin small molecules to block the action of lethal factor, the protease component of lethal toxin produced by Bacillus anthracis. This grant will support the improvement of current lethal factor inhibitors, which have demonstrated efficacy in animal models of post exposure inhalation of anthrax, as drug candidates. The safety, stability and bioavailability of these candidates will be improved with the goal of use in humans as an antidote to anthrax lethal factor intoxication.
"Research and development of vaccines and treatments to protect against infectious diseases will help keep our families and communities healthy and safe," Senator
"Our team is pleased to be able to continue our anti-toxin development work at Hawaii Biotech, where we started this program several years ago," said Dr.
Keywords for this news article include: Biotechnology, Allergies, Allergy Medicine, Anthrax Vaccines, Bacterial Vaccines,
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC
Most Popular Stories
- 5 Notable Hispanic Technology Executives
- Top Hispanic Tech Companies Push for the Top
- Rand Paul Tops Presidential Straw Poll at Conservative PAC Conference
- Tesla's Alt-Energy Future Aims for Massive Lithium-Ion Battery Production
- New Chat App, Yik Yak, Causes Problems for Students
- China Urges Malaysia Flight Emergency Response
- Gas Prices May Jump from Calif. Emissions Law
- Russia, Crimea Discuss Referendum
- Visa, MasterCard Team Up to Focus on Payment Security
- Obama Meets with Ukraine Prime Minister Wednesday